Pui C H, Ip S H, Iflah S, Behm F G, Grose B H, Dodge R K, Crist W M, Furman W L, Murphy S B, Rivera G K
Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101.
Blood. 1988 Apr;71(4):1135-7.
The clinical significance of interleukin 2 receptor (IL2R) concentrations in serum was determined for 344 children with newly diagnosed acute lymphoblastic leukemia (ALL). Serum levels of IL2R in patients (267 to 80,000 U/mL, median 2,007 U/mL) were significantly higher than normal control values (170 to 738 U/mL, median 347 U/mL) (P less than .0001). Measurements in cases of T cell ALL were lower than in the non-T, non-B cases (P = .02). Among the 264 patients with non-T, non-B ALL, but not in those with T cell disease, higher serum IL2R levels (greater than 2,000 U/mL) were associated with a poorer treatment outcome (P = .04). In a multivariate analysis, serum IL2R level contributed independent prognostic information beyond that conveyed by leukocyte count, race, and age (P = .04). One explanation for these results is that soluble IL2R competes with normal lymphocyte-integrated IL2R for the ligand and thus could suppress host antitumor immunity.
对344例新诊断的急性淋巴细胞白血病（ALL）患儿测定了血清白细胞介素2受体（IL2R）浓度的临床意义。患者血清IL2R水平（267至80,000 U/mL，中位数2,007 U/mL）显著高于正常对照值（170至738 U/mL，中位数347 U/mL）（P小于0.0001）。T细胞ALL病例的测量值低于非T、非B病例（P = 0.02）。在264例非T、非B ALL患者中，而非T细胞疾病患者中，较高的血清IL2R水平（大于2,000 U/mL）与较差的治疗结果相关（P = 0.04）。在多变量分析中，血清IL2R水平提供了超出白细胞计数、种族和年龄所传达信息的独立预后信息（P = 0.04）。这些结果的一种解释是，可溶性IL2R与正常淋巴细胞整合的IL2R竞争配体，因此可能抑制宿主抗肿瘤免疫。
